Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Cilofexor in Healthy Volunteers
NCT02654002Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cilofexor in Nonalcoholic steatohepatitis (NASH) (10 cohorts), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at Day 1, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinite Time at Day 1 and 6 more. Started Jan 2016; status: completed.
02
Drugs
cilofexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02654002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654002.